Ricardo Garcia-Monaco

Ricardo Garcia-Monaco

Auto-generated profile, based on publicly available information

Ricardo Garcia-Monaco

Hospital Italiano de Buenos Aires

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Neurosurgery
Verified
Journal Article
Closed access
PLPierre L. Lasjaunias
Pierre L. Lasjaunias
SCSoke M. Chng
Soke M. Chng
MSMarina Sachet
Marina Sachet
HAHortensia Alvarez
Hortensia Alvarez
GRGeorges Rodesch
Georges Rodesch
RGRicardo Garcia-Monaco
Ricardo Garcia-Monaco
OBJECTIVE: The vein of Galen aneurysmal malformation (VGAM) is a choroidal type of arteriovenous malformation involving the vein of Galen forerunner. This is distinct from an arteriovenous malformation with venous drainage into a dilated, but already formed, vein of Galen. Reports of endovascular treatment of VGAM in the literature approach the disease from a purely technical viewpoint and often fail to provide satisfactory midterm results. To focus the therapeutic challenge to a strictly morphological goal overlooks the fundamental aspects of neonatal and infant anatomy and fluid physiology. During the past 20 years, our approach to VGAM has remained the same. Our experience, based on 317 patients with VGAM who were studied in Hospital Bicêtre between October 1981 and October 2002, allows us to describe the angioarchitecture, natural history, and management of VGAM in neonates, infants, and children.METHODS: Of our cohort of 317 patients, 233 patients were treated with endovascular embolization; of these, 216 patients were treated in our hospital. The treatment method of choice was a transfemoral arterial approach to deliver glue at the fistulous zone.RESULTS: Of 216 patients, 23 died despite or because of the embolization (10.6%). Twenty out of the 193 (10.4%) surviving patients were severely retarded, 30 (15.6%) were moderately retarded, and 143 (74%) were neurologically normal on follow-up.CONCLUSION: Our data demonstrate that most treated children survive and undergo normal neurological development; an understanding of the clinical, anatomical, and pathophysiological features of VGAM has, therefore, reversed the former poor prognosis. Our level of understanding about the lesion allows us to predict most situations and remedy them by applying a strict evaluation protocol and working within an optimal therapeutic window. Patient selection and timing remain the keys in the management of this condition. It is more important to restore normal growth conditions than a normal morphological appearance, with the primary therapeutic objective being normal development in a child without neurological deficit.

6 July 2015 in Cancer
Verified
Journal Article
Open access
PDF file
Robert CG Martin IIRobert CG Martin II
Robert CG Martin II
CSCharles R. Scoggins
Charles R. Scoggins
MSMarshall Schreeder
Marshall Schreeder
WRWilliam S. Rilling
William S. Rilling
CLChristopher J. Laing
Christopher J. Laing
SSSteven M. Strasberg
Steven M. Strasberg
BACKGROUND: Reports have demonstrated the superior activity of combining both irinotecan and oxaliplatin (FOLFOXIRI) therapy. An option for gaining similar benefits with less toxicity would be the administration of irinotecan through a hepatic artery approach. The aim of this study was to assess the response and adverse event rates for irinotecan drug‐eluting beads (DEBIRI) with folinic acid, 5‐fluorouracil, and oxaliplatin (FOLFOX) and bevacizumab as a first‐line treatment for unresectable colorectal liver metastasis.METHODS: Patients with colorectal liver metastases were randomly assigned to modified FOLFOX (mFOLFOX) and bevacizumab or mFOLFOX6, bevacizumab, and DEBIRI (FOLFOX‐DEBIRI). The primary endpoint was the response rate. The secondary endpoints were adverse events, the rate of conversion to resection, and progression‐free survival.RESULTS: The intention‐to‐treat population comprised 70 patients: 10 patients in the pilot and then 30 patients randomly assigned to the FOLFOX‐DEBIRI arm and 30 patients randomly assigned to the FOLFOX/bevacizumab arm. The 2 groups were similar with respect to the extent of liver involvement (30% vs 30%), but a greater percentage of patients in the FOLFOX‐DEBIRI arm had an Eastern Cooperative Oncology Group performance status of 1 or 2 (57% vs 31%) and extrahepatic disease (56% vs 32%, P = .02). The median numbers of chemotherapy cycles were similar (10 vs 9), and there were similar rates of grade 3/4 adverse events (54% for the FOLFOX‐DEBIRI group vs 46% for the FOLFOX/bevacizumab group). The overall response rate was significantly greater in the FOLFOX‐DEBIRI arm versus the FOLFOX/bevacizumab arm at 2 (78% vs 54%, P = .02), 4 (95% vs 70%, P = .03), and 6 months (76% vs 60%, P = .05). There was significantly more downsizing to resection in the FOLFOX‐DEBIRI arm versus the FOLFOX/bevacizumab arm (35% vs 16%, P = .05), and there was improved median progression‐free survival (15.3 vs 7.6 months).CONCLUSIONS: The simultaneous administration of mFOLFOX6 (with or without bevacizumab) and DEBIRI through the hepatic artery (FOLFOX‐DEBIRI) is safe and does not cause treatment delays or increase the systemic toxicity of chemotherapy. This strategy leads to improved overall response rates, improved hepatic progression‐free survival, and more durable overall progression‐free survival in patients downsized to resection. Cancer 2015. © 2015 American Cancer Society. Cancer 2015;121:3649–3658. © 2015 American Cancer Society.

1 May 2007 in Neuroimaging Clinics Of North America
Verified
Journal Article
Closed access
HAH. Alvarez
H. Alvarez
RMR. Garcia Monaco
R. Garcia Monaco
GRG. Rodesch
G. Rodesch
MSM. Sachet
M. Sachet
TKT. Krings
T. Krings
PLPierre Lasjaunias
Pierre Lasjaunias

1 February 1995 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
PLPierre Lasjaunias
Pierre Lasjaunias
FHFrancis Hui
Francis Hui
MZMichel Zerah
Michel Zerah
RGRicardo Garcia-Monaco
Ricardo Garcia-Monaco
VMVeronique Malherbe
Veronique Malherbe
HAHortensia Alvarez
Hortensia Alvarez

1 May 1992 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
MZMichel Zerah
Michel Zerah
RGRicardo Garcia-Monaco
Ricardo Garcia-Monaco
GRGeorges Rodesch
Georges Rodesch
KTKarel Terbrugge
Karel Terbrugge
MTMarc Tardieu
Marc Tardieu
PLPierre Lasjaunias
Pierre Lasjaunias

1 November 1991 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
PLP. Lasjaunias
P. Lasjaunias
RGR. Garcia-Monaco
R. Garcia-Monaco
GRG. Rodesch
G. Rodesch
KBK. Ter Brugge
K. Ter Brugge
MZM. Zerah
M. Zerah
DVD. de Victor
D. de Victor